Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study - 18/04/17
, Colette Smith b, Adele Torkington c, Craig Davies c, Shazaad Ahmad c, Andrew Tomkins c, Jonathan Shaw d, Margaret Kingston d, Ghadeer Muqbill e, Philip Hay e, Larissa Mulka f, Deborah Williams f, Laura Waters g, Nataliya Brima g, Neal Marshall h, Margaret Johnson h, Mas Chaponda a, Mark Nelson iSummary |
Objectives |
Persistence with an antiretroviral therapy (ART) regimen for HIV can be defined as the length of time a patient remains on therapy before stopping or switching. We aimed to describe ART persistence in treatment naïve patients starting therapy in the United Kingdom, and to describe differential persistence by treatment regimen.
Methods |
We performed a retrospective cohort study at eight UK centres of ART-naïve adults commencing ART between 2012 and 2015. Aggregate data were extracted from local treatment databases. Time to discontinuation was compared for different third agents and NRTI backbones using incidence rates.
Results |
1949 patients contributed data to the analysis. Rate of third agent change was 28 per 100 person-years of follow up [95% CI 26–31] and NRTI backbone change of 15 per 100 person-years of follow up [95% CI 14–17]). Rilpivirine, as co-formulated rilpivirine/tenofovir/emtricitabine had a significantly lower discontinuation rate than all other third agents and, excluding single tablet regimens, co-formulated tenofovir/emtricitabine had a significantly lower discontinuation rate than co-formulated abacavir/lamivudine. The reasons for discontinuation were not well recorded.
Conclusions |
Treatment discontinuation is not an uncommon event. Rilpivirine had a significantly lower discontinuation rate than other third agents and tenofovir/emtricitabine a lower rate than co-formulated abacavir/lamivudine.
Le texte complet de cet article est disponible en PDF.Keywords : HIV, Antiretroviral therapy, ART, Persistence, Adherence
Plan
Vol 74 - N° 4
P. 401-407 - avril 2017 Retour au numéro
Article précédent
- No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors
- Petra J. Woestenberg, Audrey J. King, Marianne A.B. van der Sande, Robine Donken, Suzan Leussink, Fiona R.M. van der Klis, Christian J.P.A. Hoebe, Johannes A. Bogaards, Birgit H.B. van Benthem
- Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: A post-hoc causal inference model using the AmarCAND2 study
- Sébastien Bailly, Olivier Leroy, Elie Azoulay, Philippe Montravers, Jean-Michel Constantin, Hervé Dupont, Didier Guillemot, Olivier Lortholary, Jean-Paul Mira, Pierre-François Perrigault, Jean-Pierre Gangneux, Jean-François Timsit
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?